In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 9, 2009, Pages 3996-4001

  Finegold, Sydney M ^a,b   Bolanos, Mauricio ^a   Sumannen, Paula H ^a   Molitoris, Denise R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; DAPTOMYCIN; LINEZOLID; METRONIDAZOLE; SULTAMICILLIN; TELAVANCIN; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIA, ANAEROBIC; CLOSTRIDIUM DIFFICILE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS;

EID: 70349086951     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00908-08     Document Type: Article

References (22)

1. Aldridge, K. E. 1995. The occurrence, virulence, and antimicrobial resistance of anaerobes in polymicrobial infections. Am. J. Surg. 169:2S-7S.
2. Dvorchik, B. H., D. Brazier, M. F. DeBruin, and R. D. Arbeit. 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47:1318-1323.
3. Finegold, S. M., D. Molitoris, Y. Song, C. Liu, M. L. Vaisanen, E. Bolte, M. McTeague, R. Sandler, H. Wexler, E. M. Marlowe, M. D. Collins, P. A. Lawson, P. Summanen, M. Baysallar, T. J. Tomzynski, E. Read, E. Johnson, R. Rolfe, P. Nasir, H. Shah, D. A. Haake, P. Manning, and A. Kaul. 2002. Gastrointestinal microflora studies in late-onset autism. Clin. Infect. Dis. 35:S6-S16.
4. Goldstein, E. J. C., D. M. Citron, C. V. Merriam, Y. A. Warren, K. L. Tyrrell, and H. T. Fernandez. 2004. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob. Agents Chemother. 48:2149-2152.
5. Hatano, K., K. Matsuzaki, Y. Sato, I. Kobayashi, and K. Yamaguchi. 2007. In vitro antimicrobial activity of telavancin against methicillin-resistant Staphylococcus aureus clinical isolates from Japan (2006). J. Antibiot. (Tokyo) 60:709-712.
6. Higgins, D. L., R. Chang, D. V. Debabov, J. Leung, T. Wu, K. M. Krause, E. Sandvik, J. M. Hubbard, K. Kaniga, D. E. Schmidt, Jr., Q. Gao, R. T. Cass, D. E. Karr, B. M. Benton, and P. P. Humphrey. 2005. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:1127-1134.
7. Jansen, W. T., A. Verel, J. Verhoef, and D. Milatovic. 2007. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe. Antimicrob. Agents Chemother. 51:3420-3424.
8. Jousimies-Somer, H. R., P. Summanen, D. M. Citron, E. J. Baron, H. M. Wexler, and S. M. Finegold. 2002. Wadsworth-KTL anaerobic bacteriology manual, 6th ed. Star Publishing Co., Belmont, CA.
9. Leadbetter, M. R., S. M. Adams, B. Bazzini, P. R. Fatheree, D. E. Karr, K. M. Krause, B. M. Lam, M. S. Linsell, M. B. Nodwell, J. L. Pace, K. Quast, J. P. Shaw, E. Soriano, S. G. Trapp, J. D. Villena, T. X. Wu, B. G. Christensen, and J. K. Judice. 2004. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J. Antibiot. (Tokyo) 57:326-336.
10. Leuthner, K. D., C. M. Cheung, and M. J. Rybak. 2006. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58:338-343.
11. Lipsky, B. A., A. R. Berendt, H. G. Deery, J. M. Embil, W. S. Joseph, A. W. Karchmer, J. L. LeFrock, D. P. Lew, J. T. Mader, C. Norden, and J. S. Tan. 2006. Diagnosis and treatment of diabetic foot infections. Plast. Reconstr. Surg. 117:212S-238S.
12. MacGowan, A. P. 2003. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections. J. Antimicrob. Chemother. 51:17-25.
13. Meyers, B. R., P. Wilkinson, M. H. Mendelson, S. Walsh, C. Bournazos, and S. Z. Hirschman. 1991. Pharmacokinetics of ampicillin-sulbactam in healthy elderly and young volunteers. Antimicrob. Agents Chemother. 35:2098-2101.
14. National Committee for Clinical Laboratory Standards. 2004. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard, 6th ed. CLSI publication number M11-A6. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Plaisance, K. I., G. L. Drusano, A. Forrest, R. J. Townsend, and H. C. Standiford. 1989. Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob. Agents Chemother. 33:618-620.
16. Rubinstein, E., G. R. Corey, M. E. Stryjewski, H. W. Boucher, R. N. Daly, F. C. Genter, S. L. Barriere, M. M. Kitt, and H. D. Friedland. 2008. Telavancin for hospital-acquired pneumonia, including ventilator-associated pneumonia: the ATTAIN studies. Clin. Microbiol. Infect. 14(s7):S14.
17. Saravolatz, L. D., J. Pawlak, and L. B. Johnson. 2007. Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 60:406-409. (Pubitemid 47243894)
18. Shaw, J. P., J. Seroogy, K. Kaniga, D. L. Higgins, M. Kitt, and S. Barriere. 2005. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49:195-201.
19. Song, Y., C. Liu, M. McTeague, and S. M. Finegold. 2003. 16S ribosomal DNA sequence-based analysis of clinically significant gram-positive anaerobic cocci. J. Clin. Microbiol. 41:1363-1369.
20. Stryjewski, M. E., D. R. Graham, S. E. Wilson, W. O'Riordan, D. Young, A. Lentnek, D. P. Ross, V. G. Fowler, A. Hopkins, H. D. Friedland, S. L. Barriere, M. M. Kitt, and G. R. Corey. 2008. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin. Infect. Dis. 46:1683-1693.
21. Stryjewski, M. E., W. D. O'Riordan, W. K. Lau, F. D. Pien, L. M. Dunbar, M. Vallee, V. G. Fowler, Jr., V. H. Chu, E. Spencer, S. L. Barriere, M. M. Kitt, C. H. Cabell, and G. R. Corey. 2005. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin. Infect. Dis. 40:1601-1607.
22. Thummel, K. E., D. D. Shen, N. Isoherranen, and H. E. Smith. 2006. Design and optimization of dosage regimens: pharmacokinetic data, p. 1787-1888. In L. L. Brunton, J. S. Lazo, and K. L. Parker (ed.), Goodman & Gilman's the pharmacological basis of therapeutics, 11th ed. McGraw-Hill, New York, NY.